Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Fujian Provincial Cancer Hospital

Status and phase: Not yet enrolling; Phase 2

Conditions: VEGF; Stage IV Non-small Cell Lung Cancer; PD-1 Inhibitor; Lung Adenocarcinoma

Treatments: Drug: Serplulimab and Bevacizumab injection

Study type: Interventional

Funder types: Other

Identifiers

NCT05675033

SCOG004

Details and patient eligibility

About

In order to further evaluate the efficacy of immunotherapy combined with antivascular therapy in the real world, we used Serpluimab combined with Bevacizumab and platinum-based chemotherapy in previously untreated EGFR/ALK-negative advanced non-squamous NSCLC patients, to evaluate the efficacy and safety of this regimen.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Fully understood this study and voluntarily signed the informed consent form (ICF);

  -≥ 18 years and ≤ 75 years old;

• ECOG score 0-1;

• Non-squamous NSCLC;

• stage IV;

• EGFR and ALK negative;

• Treatment-naive;

• According to RECIST1.1 criteria, there are measurable or evaluable lesions.

Exclusion criteria

• Tumor histology or cytology confirmed that it was associated with squamous cell carcinoma or small cell lung cancer;
• Patients with severe organ dysfunction were indicated by examination, Exclude subjects with any active, known or suspected autoimmune diseases;
• The estimated survival time is less than 3 months.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

study arm

Other group

Description:

This is a single arm study.

Treatment:

Drug: Serplulimab and Bevacizumab injection